Provided by Tiger Trade Technology Pte. Ltd.

Gossamer Bio Inc.

0.4233
-1.7067-80.13%
Pre-market: 0.3935-0.0298-7.04%07:08 EST
Volume:273.89M
Turnover:114.58M
Market Cap:97.98M
PE:-0.62
High:0.6000
Open:0.5961
Low:0.3315
Close:2.13
52wk High:3.87
52wk Low:0.3315
Shares:231.46M
Float Shares:183.82M
Volume Ratio:44.47
T/O Rate:149.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6874
EPS(LYR):-0.2499
ROE:-783.37%
ROA:-34.25%
PB:-1.19
PE(LYR):-1.69

Loading ...

Gossamer Bio Currently Down Eight Consecutive Days, on Pace for Longest Losing Streak Since November 2024 -- Data Talk

Dow Jones
·
Jan 08

BRIEF-Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Dec 10, 2025

Gossamer Bio Grants Stock Options to New Employee Under Inducement Plan

Reuters
·
Dec 10, 2025

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Nov 20, 2025

Stock Track | Gossamer Bio Soars 5.30% Pre-Market as Oppenheimer Raises Price Target

Stock Track
·
Nov 10, 2025

BRIEF-Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Nov 08, 2025

Gossamer Bio Grants Stock Options to New Employees Under 2023 Inducement Plan

Reuters
·
Nov 08, 2025

Gossamer Bio Inc. to Present at Guggenheim Securities Healthcare Innovation Conference

Reuters
·
Nov 07, 2025

Gossamer Bio's Q3 net loss widens to $48.2 mln

Reuters
·
Nov 06, 2025

BRIEF-Gossamer Bio Q3 EPS USD -0.21

Reuters
·
Nov 06, 2025

Gossamer Bio Inc expected to post a loss of 19 cents a share - Earnings Preview

Reuters
·
Nov 04, 2025

EXPLAINER-How companies are steering IPO plans amid US government shutdown

Reuters
·
Oct 07, 2025

Wedbush Adjusts Gossamer Bio Price Target to $6 From $5, Maintains Outperform Rating

MT Newswires Live
·
Sep 25, 2025

Sector Update: Health Care Stocks Decline Premarket Thursday

MT Newswires Live
·
Sep 25, 2025

Gossamer Bio Issues 2.5M Shares for Merger Option, Plans Additional 1.5M Shares and Up to 6.7M in Milestone Stock Payments

Reuters
·
Sep 25, 2025

Respira Therapeutics Enters Into Agreement With Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira From Samsara Biocapital

THOMSON REUTERS
·
Sep 25, 2025

Press Release: Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital

Dow Jones
·
Sep 25, 2025

Gossamer Bio - Shareholders of Respira Eligible for Some Milestone Payments and High Single‑Digit Royalty on Potential Net Sales of Rt234

THOMSON REUTERS
·
Sep 25, 2025

Gossamer Bio Inc - IF Option Is Exercised, Gossamer Does Not Expect to Commence Clinical Trials of Rt234 Until at Least 2027

THOMSON REUTERS
·
Sep 25, 2025

Gossamer Bio Inc - to Issue 2.5 Mln Shares, 1.5 Mln More on Option Exercise

THOMSON REUTERS
·
Sep 25, 2025